Show Me the Data®: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Carrie L. Kitko, MD; Miguel-Angel Perales, MD; and Amandeep Salhotra, MD, discuss GVHD prophylaxis strategies and therapies to address treatment-naive and steroid-refractory chronic GVHD.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate emerging graft-vs-host disease (GVHD) prophylaxis strategies and their potential impact on reducing chronic GVHD (cGVHD) burden following allogeneic hematopoietic stem cell transplant
• Interpret key clinical trial data supporting the use of approved and emerging agents for cGVHD
• Apply current evidence to select the most appropriate treatment option for patients with steroid-refractory cGVHD

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Incyte Corporation and Orca Bio.

Faculty:

Carrie L. Kitko, MD

Ingram Professorship in Pediatric Oncology
Medical Director, Pediatric Stem Cell Transplant Program
Vanderbilt University Medical Center
Nashville, TN

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Incyte, Mesoblast, Sanofi

Miguel-Angel Perales, MD

Chief, Adult Bone Marrow Transplantation Service
Attending Physician and Member
Division of Hematologic Malignancies, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Allogene, Bristol Myers Squibb, Celgene, ExeVir, ImmPACT Bio, Incyte, Kite/Gilead, Merck, Miltenyi Biotec, Nektar Therapeutics, Novartis, Omeros, Orca Bio, Pierre Fabre, Sanofi, Syncopation, Takeda, VectivBio AG, Vor Bio; DSMBs: Cidara Therapeutics, SELLAS Life Sciences; Institutional research support for clinical trials: Allogene, Genmab, Incyte, Kite/Gilead, Miltenyi Biotec, Novartis, Tr1x; Ownership interests in publicly traded companies: Omeros; Ownership interests in privately held companies: Orca Bio

Amandeep Salhotra, MD

Associate Professor, Division of Leukemia
Department of Hematology and Hematopoietic Cell Transplantation
City of Hope
Duarte, CA

Disclosures: Amandeep Salhotra, MD, has no relevant financial relationships with ineligible companies.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on trends in GVHD, additional novel GVHD prophylaxis strategies, and trial design for cGVHD, go to https://www.gotoper.com/oncobyte-cgvhd.

Release Date

March 31, 2026

Expiration Date

March 31, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.